Inmune Bio, Inc. (INMB): Capital Expenditures

Annual figures by period end, from SEC filings.

$1.04M

Year ended 2025-12-31

Period ended	Capital Expenditures	Change YoY	Source filing
2025-12-31	$1.04M	n/a	2026-03-30, From 2025-01-01

Capital Expenditures at similar companies

Companies with the same SEC industry code (Biological Products, (No Diagnostic Substances)), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

Company	Year ended	Capital Expenditures	Change YoY
Inmune Bio, Inc. (INMB)	2025-12-31	$1.04M	n/a
Entera Bio Ltd. (ENTX)	2025-12-31	$107.0K	n/m
AIM ImmunoTech Inc. (AIM)	2024-12-31	$18.0K	n/a
Senti Biosciences Holdings, Inc. (SNTI)	2025-12-31	$196.0K	+653.8%
VivoSim Labs, Inc. (VIVS)	2026-03-31	$0	-100.0%
aTYR PHARMA INC (ATYR)	2025-12-31	$77.0K	+18.5%
Cardiff Oncology, Inc. (CRDF)	2025-12-31	$44.0K	-45.0%
Prokidney Corp. (PROK)	2025-12-31	$15.20M	-48.5%
Pluri Inc. (PLUR)	2026-06-30	$633.0K	-60.9%

Compare INMB, ENTX, AIM, SNTI side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗